Purpose of review Erythroid progenitors must accurately and efficiently splice thousands of pre-mRNAs as the cells undergo extensive changes in gene expression and cellular remodeling during terminal erythropoiesis. Alternative splicing choices are governed by interactions between RNA binding proteins and cis-regulatory binding motifs in the RNA. This review will focus on recent studies that define the genome-wide scope of splicing in erythroblasts and discuss what is known about its regulation.
INTRODUCTION
Most human genes produce multiple transcripts through alternative splicing of their pre-mRNAs, resulting in enormously diverse transcriptome potential. Regulation of splicing in tissue-specific and developmental patterns plays a major role in establishing the specialized phenotype of differentiated cells. The erythroid lineage is no exception, as it executes a robust alternative splicing program that governs usage of both exons and retained introns during terminal erythropoiesis [1,2 & , 3, 4 && ]. Erythroid differentiation-associated alternative splicing switches can functionally impact cell function, for example, establishment of a mechanically stable red cell membrane requires upregulation of splicing efficiency for exon 16 in the protein 4.1 (EPB41) gene. This splicing switch promotes interactions among protein 4.1, spectrin, and actin that stabilize the membrane [5] .
Programed RNA processing networks are governed by combinatorial interactions of multiple RNA binding proteins (RBPs) with cis-regulatory sequences in pre-mRNA, located in alternative exons and flanking intron sequences. Together, these interactions promote or inhibit assembly of a functional spliceosome, which catalyzes excision of the intron and religation of flanking exons during each splicing event. Key regulatory elements are often evolutionarily conserved, but prediction of alternative splicing remains difficult due to the degeneracy of RNA sequence motifs recognized by most RBPs. Nevertheless, our understanding of the 'splicing code' that governs tissue-specific splicing continues to improve [6] .
The importance of accurate splicing is underscored by the increasing number of human diseases attributed to aberrant RNA processing. Defective splicing can arise from mutations in splice sites or nearby cis-regulatory sequences, thereby disrupting expression of individual erythroid genes. Indeed, splicing mutations are relatively common and have
RNA PROCESSING ENSURES SYNTHESIS OF APPROPRIATE ERYTHROID PROTEIN ISOFORMS
The RNA processing machinery in erythroid progenitors acts on the pool of pre-mRNAs presented by the transcriptional machinery, to execute an alternative splicing program designed to engineer synthesis of protein isoforms meeting the physiological needs of differentiating erythroblasts. The protein 4.1R gene (EPB41) mentioned above is a prime example; the gene encodes diverse protein isoforms in a tissuespecific manner through judicious regulation of multiple alternative splicing choices [9] . In differentiating erythroid progenitors, the splicing machinery skips several exons that are primarily utilized in nonerythroid cells, while ensuring correct alternative splice site choices at exons 2 and 16 that are required to generate 80-kD protein isoforms with high affinity for spectrin and actin [10] [11] [12] . The mechanisms responsible for splicing of these two exons have been studied extensively [10, [13] [14] [15] [16] [17] [18] [19] [20] [21] .
RNA processing also shapes other genes' output of erythroid isoform ensembles that are distinct from nonerythroid counterparts, presumably optimizing red cell maturation. Use of tissue-specific alternative first exons facilitates expression of longer erythroid isoforms of ankyrin (ANK1) and band 3 (SLC4A1) compared with shorter isoforms in muscle and kidney, respectively, that are transcribed from internal promoters [22, 23] . Conversely, erythroid beta spectrin is shorter at the C-terminus than its muscle counterpart due to differential polyadenylation and splice site usage that prevents expression of 3 0 coding exons [24] . Very recently, selection of an alternative polyadenylation site in intron 17 was reported to generate 3 0 truncated isoforms of EPB41 mRNA [25] , but the impact of this splicing variant on erythroid biology is unknown. Even the relatively simple GATA1 gene can be subject to a domain-altering splicing event: for example, alternative splicing of exon 2 can control expression of a transcription activation domain. In mouse fetal liver erythroblasts, upregulation of specific NDEL1 isoform is critical for enucleation in late erythroblasts [1] . Alternative splicing can generate alternative isoforms of acyl-CoA synthetase ACSL6 with differential substrate specificities presumably required to generate and repair many lipid species in erythroid membranes [26] .
ERYTHROBLASTS EXECUTE AN EXTENSIVE STAGE-SPECIFIC PROGRAM OF ALTERNATIVE SPLICING, AFFECTING BOTH EXONS AND INTRONS, DURING TERMINAL ERYTHROPOIESIS
Genome-wide studies of erythroid alternative splicing have been facilitated by RNA-seq analysis of defined cell populations [1, 3, 27 ]. An excellent model system is a series of RNA-seq libraries prepared from fluorescence-activated cell sorter-purified proerythroblasts, early basophilic erythroblasts, late basophilic erythroblasts, polychromatophilic erythroblasts, and orthochromatophilic erythroblasts, the last stage before enucleation [28] . Analysis of the data revealed an extensive alternative splicing program analogous to that found in other nucleated cell types. Alternative splicing is enriched for genes functioning in RNA processing, cell cycle regulation, organelle organization, and chromatin structure and function [3] , suggesting that multiple isoforms of important erythroid proteins are expressed in these cells. Dynamic regulation of splicing transitions during terminal erythropoiesis can drive changes in protein isoform expression to add new functionalities advantageous for late erythroblasts and/or red cells. In the EPB41 gene, the switch from predominant E16 skipping in early cells to inclusion in late erythroblasts (Fig. 1a) can be visualized at the genome browser by a substantial increase in RNA-seq reads mapped to the E16 peak (Fig. 1b) . Calculated PSI (percentage spliced in) values during terminal erythropoiesis
KEY POINTS
An extensive program of differentiation stage-specific alternative splicing events is expressed during terminal erythropoiesis.
Alternative splicing of coding exons can introduce new functionality, whereas splicing of PTC-containing exons can posttranscriptionally downregulate production of translatable mRNA.
Mutations that disrupt splice site choice or compromise expression of splicing regulators can cause erythroid disease.
Better understanding splicing mechanisms should lead to therapy for splicing diseases.
( Fig. 1c) depicts this progressive increase in E16 splicing as erythroblasts mature. In contrast to this 'productive' splicing transition, other splicing transitions introduce premature termination codons (PTCs) that mark transcripts for rapid degradation via nonsense-mediated decay (NMD). An example of alternative splicing coupled to NMD (AS-NMD) is shown in Fig. 2 for the SNRNP70 splicing factor gene. The PTC exon is mostly skipped in early erythroblasts, but inclusion is upregulated in mature cells leading to increased NMD [3] . AS-NMD can thereby function as a posttranscriptional mechanism to downregulate gene expression [3] .
Erythroid gene expression is also regulated by intron retention, in which a transcript is polyadenylated and spliced at most introns but remains unspliced at one or more introns [2
]. Hundreds of retained introns are dynamically regulated during terminal erythropoiesis, exhibiting low intron retention in early progenitors but much higher intron retention -sometimes reaching 20-50% -in late erythroblasts. This intron retention class is enriched in RNA-processing genes, especially splicing factors including SF3B1 and SNRNP70, but it also includes other important genes such as alpha spectrin (SPTA1). Figure 3 summarizes the regulation of SF3B1 intron 4 during terminal erythropoiesis. The relevant gene region is shown in Fig. 3a , whereas RNA-seq mapping data reveal elevated intron retention in late erythroblasts (Fig. 3b) , as does the PIR (percentage intron retention) profile during terminal erythropoiesis (Fig. 3c) . In contrast to SF3B1, other genes contain introns that maintain high but stable intron retention level across erythroblast populations [4 && ]. Prominent in this group are the mitochondrial iron importers mitoferrin1 and mitoferrin2 (SLC25A37 and SLC25A28) that are critical for heme biosynthesis. Many intron retention transcripts are retained in the nucleus where they are resistant to NMD but not translated into protein, contributing to a discordance between transcript and protein abundance in some genes [29 & ]. The function of intron retention is not well understood. It may represent a posttranscriptional limit to gene expression, or it could provide a reservoir for new mRNA production in response to appropriate signals.
REGULATION OF THE ERYTHROID SPLICING PROGRAM
Master regulator(s) of the erythroid splicing program are not well defined as yet. Among splicing factors known to drive developmental splicing transitions in nonerythroid cells, the zinc finger RBPs known as MBNL1 and MBNL2 are leading candidates for performing this role in erythroblasts. Depending on the location of binding, MBNL proteins can regulate splicing, polyadenylation, RNA stability, and RNA localization in several systems [30] [31] [32] [33] [34] [35] [36] . Deficits in MBNL function also have disease relevance. Patients with the triplet repeat disease myotonic dystrophy, in which expansion of the nucleotide sequence CUG occurs in DMPK mRNA, exhibit many splicing defects due to titration of MBNL activity away from pre-mRNA substrates [37] . In the erythroid system, MBNL binding motifs are enriched near exons that undergo developmental splicing transitions [1]; moreover, MBNL1 knockdown in mouse fetal liver alters splicing of transcripts such as Epb4.1 and Ndel1 and inhibits erythroblast enucleation [1]. Together these results suggest an important role for Mbnl1 during erythroid terminal differentiation.
Much work remains to be done in this area to identify positive and negative regulators of erythroid splicing events and splicing transitions that are not attributable to regulation by MBNL proteins. A few highly expressed RBPs with demonstrated ability to regulate of erythroid splicing event(s) will be mentioned here. PCBP1 and 2 (also known as aCP, or hnRNP E proteins) increase the stability of alpha globin via binding to C-rich sequences in the 3 0 UTR [38, 39] . Unexpectedly, knockdown in K562 cells revealed that they also regulate alternative splicing events, especially for exons with C-rich regions in the upstream pyrimidine tract [40 && ]. RBM38 is an RBP that is dramatically upregulated in late erythroblasts and is a known regulator of EBP41 splicing [41] ; additional functions are suggested by genetic linkage studies showing that the RBM38 gene is near a genome-wide association study (GWAS) marker for a red cell phenotype (MCV) [42,43 & ]. HNRNP A1 is highly expressed in early erythroblasts but downregulated in more mature cells; it negatively regulates the EPB41 E16 splicing switch [14] . Analogous to the role of related HNRNP proteins in suppressing differentiated splicing events in other cell types [44, 45] , A1 could be a general repressor of erythroblast splicing transitions. Finally, little is known about upstream signaling pathways that might activate splicing factors expression or function; in that regard, activation of a MAPK p38 signaling pathway can promote E16 splicing [21] .
CIS-ACTING MUTATIONS THAT DISRUPT SPLICING ARE A COMMON CAUSE OF ERYTHROID DISEASE
Point mutations within exons or their flanking introns can disturb splicing of numerous erythroid transcripts. Splicing mutants often manifest as low expression alleles due to exon skipping or alterations of splice site choice that change translational reading frame, introduce premature termination codons (PTCs), and activate NMD. Such mutations 
% intron retention (PIR)
pro ebaso lbaso poly ortho are a common cause of beta thalassemia as well as red cell membrane disorders including hereditary pyropoikilocytosis, hereditary elliptocytosis, and hereditary spherocytosis marked by deficiency of EPB41 [46] , alpha spectrin (Ref. [47] and references within) and band 3 genes [48] . A representative example is shown in Fig. 4 for the spectrin a LEPRA mutant, in which a splice site mutation at exon 37 leads to exon skipping, a translational frameshift, and NMD [49] . Unfortunately, intronic mutations can be difficult to discern by exome or transcriptome sequencing, as the effect of SNPs on splicing is not easy to predict, the mutations can reside deeper within the introns, or the affected transcript may be rapidly degraded.
Nonsense mutations in tissue-specific alternative exons can sensitize selected transcript isoforms to NMD, leading to tissue-specific protein deficiency. Deletion of a single nucleotide in E16 of the protein 4.1 gene introduces a PTC that activates NMD, causing an EPB41-deficient hereditary elliptocytosis [50] . However, 4.1R transcripts in lymphoid cells naturally skip E16, escape NMD, and express normal amounts of lymphoid 4.1R mRNA.
Disturbing the isoform balance among alternatively spliced transcripts can also cause erythroid disease. In the GATA1 gene, partial skipping of exon 2 occurs naturally to generate transcripts encoding a shortened protein isoform termed GATA1s. However, 3 0 splice site mutations that virtually eliminate exon 2 splicing are found in patients with Diamond-Blackfan anemia or dyserythropoietic anemia with megakaryocyte dysplasia [51,52 & ], in whom the deficiency of full length GATA1 compromises erythropoiesis. Altered splicing of mitoferrin-1 transcripts has been found in rare erythropoietic protoporphyria patients that do not have the typical defects in ferrochelatase [53] . These patients show elevated splicing at a cryptic 5 0 splice site in intron 2 that introduces a PTC predicted to cause NMD. Significantly, the aberrant isoform is expressed at a low level in normal erythroblasts but overexpressed for unknown reasons in patients.
MUTATIONS OR DEFICIENCIES IN CORE SPLICING MACHINERY CAN CAUSE ERYTHROID DISEASE
Mutations that alter expression of basic RNA processing machinery cause widespread defects in splicing that underlie many human genetic diseases (reviewed in [8 & ,54] 
CONCLUSION
Differentiating erythroblasts elaborate a robust alternative splicing program that stage-specifically remodels the transcriptome. Most splicing transitions are temporally coordinated with extraordinary cellular remodeling that culminates in enucleation. Splicing transitions can also downregulate expression via NMD-mediated degradation of transcripts containing PTCs. Aberrant splicing of individual transcripts, or networks of transcripts regulated by a common splicing factor, underlies numerous erythroid diseases. Understanding regulation of erythroid splicing may provide insights required for therapy of erythroid splicing diseases.
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